One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular DiseasesSurgery and InterventionCataracts

Insights Into Cataract Surgery Outcomes In Age-Related Macular Degeneration: Real-World Perspectives Across Severity Grades

Ophthalmol Retina

Ho Ssl L, Vaghefi SA, Riemer T, Kabiri P, Bonaventura T, Ru Bsam A, Joussen AM, Zeitz O

doi: 10.1016/j.oret.2024.11.018

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular Diseases

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Ophthalmol Ther

Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D

doi: 10.1007/s40123-025-01140-z

Macular Diseases

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Ophthalmol Ther

Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V, Fight Retinal Blindness! Study Group

doi: 10.1007/s40123-024-00983-2

Uveitis

Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes

Retina

Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, Nicholson L, Papasavvas I, Tucker WR, Yeung I

doi: 10.1097/IAE.0000000000004394

Related content

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Insights Into Cataract Surgery Outcomes In Age-Related Macular Degeneration: Real-World Perspectives Across Severity Grades

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes